Increased plasma myeloperoxidase levels in systemic lupus erythematosus

Increased plasma myeloperoxidase levels in systemic lupus erythematosus

Autor Telles, Rosa Weiss Google Scholar
Ferreira, Gilda Aparecida Google Scholar
Silva, Neusa Pereira da Autor UNIFESP Google Scholar
Sato, Emilia Inoue Autor UNIFESP Google Scholar
Instituição Universidade Federal de São Paulo (UNIFESP)
Brazilian Soc Rheumatol
Universidade Federal de Minas Gerais (UFMG)
Resumo The objective of the study was to quantify plasma myeloperoxidase (MPO) levels in systemic lupus erythematosus (SLE) patients and to evaluate a correlation between MPO levels and disease activity. 71 female SLE patients and 70 controls were studied. Patients were divided into two groups: Group I (n = 48) with SLEDAI-2K score 0-5 and Group II (n = 23) with SLEDAI-2K score a parts per thousand yen6. Mann-Whitney test and Spearman rank correlation were used. Two-sided P values < 0.05 were considered significant and P values a parts per thousand yen0.05 and < 0.08 were considered as a tendency. the median age of patients and controls were comparable and the mean disease duration was 99.2 +/- A 61.7 months. MPO levels were higher in patients than controls [5.99 (4.38-8.64) vs. 5.00 (3.33-7.08) ng/ml, P = 0.02]. We did not find correlation between MPO levels and SLEDAI-2k (r = 0.07, P = 0.58). MPO levels were not affected by treatment with prednisone, cyclophosphamide or azathioprine, however, a tendency of lower levels was observed among patients under antimalarial drugs. There was no significant difference in MPO plasma levels between Group I and Group II (5.83 vs. 6.02 ng/ml, P = 0.99). MPO levels were higher in patients with arthritis than in those without arthritis (8.15 vs. 5.56 ng/ml, P = 0.010). No difference was observed among patients with and without other organs/systems involvement. SLE patients presented increased MPO plasma levels than healthy controls. Despite the lack of correlation between MPO plasma levels and disease activity, the higher MPO levels in patients with articular involvement suggests MPO may play a different role in the inflammatory process of some SLE manifestations.
Assunto Systemic lupus erythematosus
Disease activity
Idioma Inglês
Financiador Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)
Brazilian Society of Rheumatology-PRONUCLEAR Program
Número do financiamento FAPESP: 05/54420-4
Data 2010-04-01
Publicado em Rheumatology International. New York: Springer, v. 30, n. 6, p. 779-784, 2010.
ISSN 0172-8172 (Sherpa/Romeo, fator de impacto)
Editor Springer
Extensão 779-784
Direito de acesso Acesso restrito
Tipo Artigo
Web of Science WOS:000275755800012

Mostrar registro completo

Arquivos deste item

Arquivos Tamanho Formato Visualização

Não existem arquivos associados a este item.

Este item aparece na(s) seguinte(s) coleção(s)